Compliance Beyond the Mock Audit
Uncover Detailed Program Intelligence
Rx|X has developed a proprietary audit tool, Avanti340B, to oversee the data connections and team processes that power procurement and inventory management of 340B drugs. Avanti340B allows teams to go beyond patient transaction testing and provides insights into issues that can cloud the performance of split-billing software.
Clients can subscribe to quarterly use of the top, managed by Rx|X experts. Gain enhanced program visibility and turn results into actions to improve mapping, unit conversions, billing units and buyer processes. Reimplementing or changing split-billing vendors? Have a manufacturer good-faith inquiry on purchasing? Avanti340B is your tool to unlocking deeper analytical views.
Build your Best Program
To explore optimal use of 340B, Rx|X utilizes a process developed over several years, 340B/360©. The idea behind 340B/360© is to evaluate the whole of an entity’s pharmaceutical use—both the areas that are currently using 340B and those that are not and identifying ways to optimize the sum of both parts.
As program evaluators with over 25 years in the field, we built a novel framework to assess the current state and future state through data review, interviews, and collaboration with the entity to understand their 340B program’s unique potential. As part of 340B/360©, Rx|X will work with the team on implementing recommendations and best practices in program documentation and organization.